BriaCell Therapeutics (TSX:BCT) Institutional Ownership : 0.02% (As of Mar. 02, 2025)

View and export this data going back to 2006. Start your Free Trial

What is BriaCell Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, BriaCell Therapeutics's institutional ownership is 0.02%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, BriaCell Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, BriaCell Therapeutics's Float Percentage Of Total Shares Outstanding is 96.15%.

BriaCell Therapeutics Institutional Ownership Historical Data

The historical data trend for BriaCell Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Institutional Ownership Chart

BriaCell Therapeutics Historical Data

The historical data trend for BriaCell Therapeutics can be seen below:

	2024-04-30	2024-05-31	2024-06-30	2024-07-31	2024-08-31	2024-09-30	2024-10-31	2024-11-30	2024-12-31	2025-01-31
Institutional Ownership	0.06	0.05	0.05	0.05	0.04	0.02	0.02	0.02	0.02	0.02

BriaCell Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

BriaCell Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (TSX:BCT) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

BCTX:USA 8BT0:Germany 8BT0:Germany

Address

235-15th Street, Suite 300, 3rd Floor, Bellevue Centre, West Vancouver, Vancouver, BC, CAN, V7T 2X1

Website

https://www.briacell.com

BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

Executives

Jamieson Bondarenko	Director
Marc Lustig	10% Security Holder, Director
Gadi Levin	Senior Officer
William Williams	Director, Senior Officer

BriaCell Therapeutics Headlines

No Headlines